Fentanyl pectin nasal spray: In breakthrough pain in opioid-tolerant adults with cancer

CNS Drugs

Volumn 25, Issue 6, 2011, Pages 511-522

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Cancer pain; Fentanyl; Intranasal

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; FENTANYL; HYDROMORPHONE; HYPNOTIC AGENT; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PHENOTHIAZINE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEDATIVE AGENT; TRANQUILIZER; WARFARIN;

ANALGESIA; ANURIA; ARTICLE; BRADYCARDIA; BREAKTHROUGH PAIN; BURNING SENSATION; CANCER PAIN; CONSTIPATION; CONTROLLED DRUG RELEASE; COUGHING; CYANOSIS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; DYSPNEA; EPISTAXIS; EUPHORIA; GENE DELIVERY SYSTEM; HISTAMINE RELEASE; HUMAN; HYPOTENSION; HYPOTHERMIA; LONG TERM CARE; MAINTENANCE THERAPY; MIOSIS; NAUSEA AND VOMITING; NOSE OBSTRUCTION; OPIATE ADDICTION; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RHINORRHEA; SEDATION; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; SORE THROAT; TASTE DISORDER; THORAX PAIN; UNCONSCIOUSNESS; UPPER RESPIRATORY TRACT OBSTRUCTION; VASODILATATION;

ANALGESICS, OPIOID; DRUG TOLERANCE; FENTANYL; HUMANS; NASAL SPRAYS; NEOPLASMS; PAIN; PECTINS;

EID: 79958192467     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11207470-000000000-00000     Document Type: Article

References (30)

1. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81 (1-2): 129-34. (Pubitemid 29199908)
2. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13 (4): 331-8.
3. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009 Mar; 3 (1): 1-6.
4. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: assessment. Pharm Ther 2005 May; 30 (5): 296-301. (Pubitemid 40734311)
5. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther 2005 Jun; 30 (6): 354-61. (Pubitemid 40885216)
6. Grape S, Schug SA, Lauer S, et al. Formulations of fentanyl for the management of pain. Drugs 2010; 70 (1): 57-72.
7. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med 2009; 12 (10): 947-54.
8. Dale O. Intranasal administration of opioids/fentanyl: phy- siological and pharmacological aspects. Eur J Pain Suppl 2010; 4 (3): 187-90.
9. Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered in-tranasally. Clin Ther 2009; 31 (12): 2954-87.
10. Watts P, Smith A. PecSys: in situ gelling system for opti- mised nasal drug delivery. Expert Opin Drug Deliv 2009 May; 6 (5): 543-52.
11. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999 Feb; 90 (2): 576-99. (Pubitemid 29071528)
12. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an up- dated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61 (15): 2289-307. (Pubitemid 34074808)
13. Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at m, d and k opiate receptors. Eur J Pharmacol 1992 Mar 24; 213 (2): 219-25.
14. Narita M, Imai S, Itou Y, et al. Possible involvement of m1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci 2002; 70 (20): 2341-54. (Pubitemid 34261045)
15. PecFent 100 and 400 micrograms/spray nasal spray solution: summary of product characteristics. London: European Medicines Agency, 2011 Jan 7.
16. Bilfinger TV, Fimiani C, Stefano GB, et al. Morphine's im- munoregulatory actions are not shared by fentanyl. Int J Cardiol 1998 Apr; 64 Suppl. 1: 61-6.
17. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56 (2): 93-6. (Pubitemid 12164872)
18. Fisher A, Watling M, Smith A, et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010 Feb; 48 (2): 138-45.
19. Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800mg in healthy volunteers. Int J Clin Pharmacol Ther 2010 Dec; 48 (12): 860-7.
20. Davis G, Knight A, Love R, et al. Rapid pain relief with fentanyl citrate nasal spray (Nasalfent) in cancer patients with breakthrough pain [abstract no. 712]. 10th Congress of the European Association for Palliative Care; 2007 Jun 7-9; Budapest: 175.
21. Davis G, Knight A, Love R, et al. Nasalfent, a novel intra- nasal formulation of fentanyl is rapidly effective and well-tolerated during treatment of breakthrough cancer pain [abstract no. 711]. 10th Congress of the European Association for Palliative Care; 2007 Jun 7-9; Budapest: 175.
22. Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010 Dec; 151 (3): 617-24.
23. Fallon M, Gatti A, Davies A, et al. Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multi-centre, double-blind, double-dummy, multiple-crossover study [abstract no. 29LBA]. Eur J Cancer Suppl 2009; 7 (2-3): 15.
24. Plus poster presented at the 15th Congress of the European CanCer Organization and 34th Congress of the European Society for Medical Oncology; 2009 Sep 20-24; Berlin.
25. Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients [published erratum appears in J Opioid Manag 2010 Nov-Dec; 6 (6): 407]. J Opioid Manag 2010 Sep-Oct; 6 (5): 319-28.
26. Torres LM, Brooks D, Gabrail N, et al. Successful titration of fentanyl pectin nasal spray in a broad range of patient types for the treatment of breakthrough cancer pain [abstract no. 1239PD]. Ann Oncol 2010 Oct; 21 Suppl. 8: viii377-8.
27. Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010; 8 (4): 184-90.
28. Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011 Feb; 41 (2): 358-66.
29. Radbruch L, Torres LM, Ellershaw JE, et al. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. Epub 2011 Mar 22.
30. Brooks D, Torres LM, Gabrail N, et al. Impact of epistaxis on the use of fentanyl pectin nasal spray to treat breakthrough cancer pain [abstract no. 1265P]. Ann Oncol 2010 Oct; 21 Suppl. 8: viii385